⏱ News is delayed by 15 minutes. Sign in for real-time access.
Sign in
ATRA News
Atara Biotherapeutics, Inc
Engineered T Cells Market - Global Forecast 2026-2032 | CAR-T, TCR-T, and Allogeneic Platforms Unlock 8.06% CAGR and a USD 41.99 Billion Opportunity
globenewswire.com
ALLO
AMGN
ATRA
AUTL
BB
BMY
CRSP
FATE
GILD
IMCR
REGN
PFE
SANG
TCRT
Atara Biotherapeutics Reports that the Resubmitted Tabelecleucel (Tab-cel®) Biologics License Application Has Been Accepted by the U.S. Food and Drug Administration
businesswire.com
ATRA
Atara Biotherapeutics, Inc. (ATRA) Investigation: Bronstein, Gewirtz & Grossman, LLC Encourages Shareholders to Contact the Firm to Learn More About the Investigation
accessnewswire.com
ATRA
Bronstein, Gewirtz & Grossman, LLC Initiates an Investigation Into Allegations Against Atara Biotherapeutics, Inc. (ATRA) And Encourages Stockholders to Reach Out
accessnewswire.com
ATRA
Bronstein, Gewirtz & Grossman, LLC Is Investigating Atara Biotherapeutics, Inc. (ATRA) and Encourages Stockholders to Connect
accessnewswire.com
ATRA
Global Cell & Gene Therapy Market Size and Forecast Report 2026-2036 | Market to Reach US$126.86 Billion at 17.3% CAGR as CRISPR, CAR-T and Scalable Manufacturing Drive Growth
globenewswire.com
ALLO
ATRA
BEAM
BMRN
BMY
CRSP
GILD
INTC
JNJ
NVS
VRTX
Atara Biotherapeutics, Inc. (ATRA) Investigation: Bronstein, Gewirtz & Grossman, LLC Encourages Stockholders to Contact the Firm to Learn More About the Investigation
accessnewswire.com
ATRA
Atara Biotherapeutics Reports that the Tabelecleucel Biologics License Application Has Been Resubmitted to the U.S. Food and Drug Administration
businesswire.com
ATRA
Bronstein, Gewirtz & Grossman, LLC Initiates an Investigation into Allegations Against Atara Biotherapeutics, Inc. (ATRA) And Encourages Investors to Reach Out
accessnewswire.com
ATRA
Bronstein, Gewirtz & Grossman, LLC Initiates an Investigation into Allegations Against Atara Biotherapeutics, Inc. (ATRA) And Encourages Stockholders to Reach Out
accessnewswire.com
ATRA